Active surveillance (AS) may be an appropriate management option in carefully selected prostate cancer (PCa) patients with a baseline PSA level of 10 ng/mL or higher, according to study findings presented at the American Urological Association annual meeting. The study showed that these patients are no more likely to experience pathologic progression that patients with lower PSA levels at baseline.

Read the article.

Leave a Comment

Scroll to Top